Study of the Transcript and Protein Expression of Poliovirus Receptor (CD155 Protein) on Colorectal Cancer Cell Line

Document Type : Original Article (s)

Authors

1 PhD Candidate , Department of Microbiology, School of Biological Sciences, Shahid Beheshti University, Tehran, Iran

2 Associate Professor, Department of Microbiology, School of Biological Sciences, Shahid Beheshti University, Tehran, Iran

3 Associate Professor, Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

4 Assistant Professor, Stem Cell Research Center AND Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

5 Professor, Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Abstract

Background: Poliovirus receptor (CD155 protein or PVR) expressed on many types of cells and exerts diverse functions. Several studies have demonstrated that changes in CD155 expression in cancer cell lines affect metastasis, proliferation, and migration. The purpose of the present study was to investigate the transcript and protein expression of CD155 in human colon adenocarcinoma cell lines in comparison to normal fetal human colon (FHC) cells.Methods: The CD155 expression levels in a human adenocarcinoma cell line and normal colon cell line were evaluated using the quantitative real-time polymerase chain reaction (PCR) and flow cytometry. All statistical analyses were performed using SPSS software at the statistical significance level of P < 0.050.Findings: Real-time polymerase chain reaction indicated that CD155 significantly overexpressed in human adenocarcinoma cell line significantly more than normal fetal cells (P < 0.001). Flow cytometry showed that protein was strongly expressed in cancer cell line and SW480 cell line showed the highest CD155 protein expression level of 98.0%, whereas this protein expression was 1.3% in human normal colon cell line (P < 0.001).Conclusion: Collectively, these data indicate that CD155 expression is frequently elevated in cancer cell line. The preferential expression of CD155 on cancer cell line rather than on normal cell line suggests that CD155 could be targeted for future poliovirus virotherapy.

Keywords

References

  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1975-2002. Bethesda, MD: National Cancer Institute; 2002.
  2. Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. UpToDate [Online]. [cited 2010]; Available from: URL: http://www.uptodate.com/contents/colorectal-cancer-epidemiology-risk-factors-and-protective-factors
  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-E386.
  5. Zhivotovsky B, Orrenius S. Carcinogenesis and apoptosis: paradigms and paradoxes. Carcinogenesis 2006; 27(10): 1939-45.
  6. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61(7-8): 554-71.
  7. Ries SJ, Brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004; 9(17): 759-68.
  8. Singh PK, Doley J, Kumar GR, Sahoo AP, Tiwari AK. Oncolytic viruses and their specific targeting to tumour cells. Indian J Med Res 2012; 136(4): 571-84.
  9. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28(7): 326-33.
  10. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003; 4(1): 7-11.
  11. Blondel B, Duncan G, Couderc T, Delpeyroux F, Pavio N, Colbere-Garapin F. Molecular aspects of poliovirus biology with a special focus on the interactions with nerve cells. J Neurovirol 1998; 4(1): 1-26.
  12. Tolskaya EA, Romanova LI, Kolesnikova MS, Ivannikova TA, Smirnova EA, Raikhlin NT, et al. Apoptosis-inducing and apoptosis-preventing functions of poliovirus. J Virol 1995; 69(2): 1181-9.
  13. Koike S, Horie H, Ise I, Okitsu A, Yoshida M, Iizuka N, et al. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J 1990; 9(10): 3217-24.
  14. Faris RA, McEntire KD, Thompson NL, Hixson DC. Identification and characterization of a rat hepatic oncofetal membrane glycoprotein. Cancer Res 1990; 50(15): 4755-63.
  15. Chadeneau C, LeMoullac B, Denis MG. A novel member of the immunoglobulin gene superfamily expressed in rat carcinoma cell lines. J Biol Chem 1994; 269(22): 15601-5.
  16. Lim YP, Fowler LC, Hixson DC, Wehbe T, Thompson NL. TuAg.1 is the liver isoform of the rat colon tumor-associated antigen pE4 and a member of the immunoglobulin-like supergene family. Cancer Res 1996; 56(17): 3934-40.
  17. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004; 4: 73.
  18. Ikeda W, Kakunaga S, Itoh S, Shingai T, Takekuni K, Satoh K, et al. Tage4/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration. J Biol Chem 2003; 278(30): 28167-72.
  19. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 2001; 49(2): 236-40.
  20. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci U S A 2000; 97(12): 6803-8.
  21. Mueller S, Wimmer E. Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v)beta3 integrin-containing membrane microdomains. J Biol Chem 2003; 278(33): 31251-60.
  22. Sato T, Irie K, Ooshio T, Ikeda W, Takai Y. Involvement of heterophilic trans-interaction of Necl-5/Tage4/PVR/CD155 with nectin-3 in formation of nectin- and cadherin-based adherens junctions. Genes Cells 2004; 9(9): 791-9.
  23. Fujito T, Ikeda W, Kakunaga S, Minami Y, Kajita M, Sakamoto Y, et al. Inhibition of cell movement and proliferation by cell-cell contact-induced interaction of Necl-5 with nectin-3. J Cell Biol 2005; 171(1): 165-73.
  24. Ikeda W, Kakunaga S, Takekuni K, Shingai T, Satoh K, Morimoto K, et al. Nectin-like molecule-5/Tage4 enhances cell migration in an integrin-dependent, Nectin-3-independent manner. J Biol Chem 2004; 279(17): 18015-25.
  25. Kakunaga S, Ikeda W, Shingai T, Fujito T, Yamada A, Minami Y, et al. Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling. J Biol Chem 2004; 279(35): 36419-25.
  26. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56(5): 855-65.
  27. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 1990; 63(2): 353-62.
  28. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, et al. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 1991; 88(3): 951-5.
  29. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2: e71.
  30. Baury B, Masson D, McDermott BM, Jr., Jarry A, Blottiere HM, Blanchardie P, et al. Identification of secreted CD155 isoforms. Biochem Biophys Res Commun 2003; 309(1): 175-82.
  31. Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res 2015; 35(4): 2287-97.
  32. Iguchi-Manaka A, Okumura G, Kojima H, Cho Y, Hirochika R, Bando H, et al. Increased soluble CD155 in the serum of cancer patients. PLoS One 2016; 11(4): e0152982.
  33. Atsumi S, Matsumine A, Toyoda H, Niimi R, Iino T, Sudo A. Prognostic significance of CD155 mRNA expression in soft tissue sarcomas. Oncol Lett 2013; 5(6): 1771-6.
  34. Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y, et al. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci 2010; 101(5): 1326-30.
  35. Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 2004; 10(14): 4831-8.
  36. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol 2004; 6(3): 208-17.
  37. Toyoda H, Ido M, Hayashi T, Gabazza EC, Suzuki K, Kisenge RR, et al. Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int J Oncol 2004; 24(1): 49-58.
  38. Atsumi S, Matsumine A, Toyoda H, Niimi R, Iino T, Nakamura T, et al. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus. Int J Oncol 2012; 41(3): 893-902.
Journal of Isfahan Medical School
Volume 35, Issue 427 - Serial Number 427
March and April 2017
Pages 453-462

Files

History

  • Receive Date: 02 May 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics